Welcome to our dedicated page for Regulus Therapeu SEC filings (Ticker: RGLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a microRNA biotech like Regulus Therapeutics Inc. (RGLS) isn’t easy—clinical data, patent charts and experimental biomarkers can bury the numbers you need. If you have ever searched for “Regulus Therapeutics insider trading Form 4 transactions” or wondered which trial update moved the share price, you know the challenge.
Stock Titan solves it. Our AI-powered summaries translate every 10-K annual report, 10-Q quarterly earnings report and sudden 8-K material event into plain English. Instead of combing through hundreds of pages, you get instant highlights on R&D spend, FDA feedback and the latest cash runway projections. Need transaction detail? We surface “Regulus Therapeutics Form 4 insider transactions real-time,” flagging each “Regulus Therapeutics executive stock transactions Form 4” the moment it hits EDGAR.
Use the platform to:
- Follow every “Regulus Therapeutics quarterly earnings report 10-Q filing” and see pipeline costs broken down by candidate.
- Read a “Regulus Therapeutics annual report 10-K simplified” to spot patent expirations or milestone payments.
- Dive into a “Regulus Therapeutics proxy statement executive compensation” without wading through legal prose.
- Get a concise “Regulus Therapeutics earnings report filing analysis” that links clinical milestones to cash burn.
- See “Regulus Therapeutics 8-K material events explained” within minutes of publication.
Whether you’re “understanding Regulus Therapeutics SEC documents with AI” for investment decisions or monitoring compliance, Stock Titan delivers comprehensive coverage, real-time alerts and expert context—so you act before the market does.
Regulus Therapeutics Inc. (RGLS): Schedule 13G/A disclosure summarizing Point72 filings. Point72 Asset Management, Point72 Capital Advisors Inc. and Steven A. Cohen report beneficial ownership of 241,157 shares, representing 0.3% of the outstanding common stock on a diluted basis. The filing states these shares include shares issuable upon exercise of warrants and that Point72 entities hold shared voting and dispositive power over 241,157 shares with no sole voting or dispositive power. The ownership percentage is calculated using a total of 69,475,246 shares outstanding, which includes the 241,157 warrant shares.
Regulus Therapeutics Inc. is the subject of a Schedule 13G/A filed by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin reporting that none of the reporting persons beneficially own any shares of Regulus common stock. The filing lists 0 shares and 0.00% ownership, with beneficial ownership calculated using an issuer share count of 69,234,089 common shares outstanding.
The reporting persons state the securities were not acquired to influence control of the issuer and that the filing is made on behalf of each undersigned. This disclosure indicates the filers currently hold no economic or voting interest in Regulus and do not represent a change in ownership or control.
FAQ
What is the current stock price of Regulus Therapeu (RGLS)?
What is the market cap of Regulus Therapeu (RGLS)?
